PHASE-II TRIAL OF CARBETIMER IN METASTATIC MELANOMA

Authors
QUAN WDY MITCHELL MS
Citation
Wdy. Quan et Ms. Mitchell, PHASE-II TRIAL OF CARBETIMER IN METASTATIC MELANOMA, Investigational new drugs, 11(2-3), 1993, pp. 231-233
Citations number
10
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
11
Issue
2-3
Year of publication
1993
Pages
231 - 233
Database
ISI
SICI code
0167-6997(1993)11:2-3<231:PTOCIM>2.0.ZU;2-O
Abstract
A phase II study of the synthetic polyelectrolyte Carbetimer 6500 mg/m 2 IV daily for five days every 21-day cycle was conducted in patients with metastatic melanoma. No responses were seen in 18 evaluable patie nts. Two patients had stable disease for five months. Toxicity was gen erally manageable and included mild hyperphosphatemia, mild proteinuri a, fatigue, pain at the injection site, and nausea. Carbetimer is inac tive in metastatic melanoma at this dose and schedule.